Highlights

  • Micro-X (ASX:MX1) has appointed Dr Brian Gonzales as chief executive as part of a broader strategic reset.
  • FY2026 Revenue increased, but product sales represented only part of the total, with development contracts and grants remaining significant.
  • The company continues to advance Rover Plus, Head CT and US development programs while managing a constrained cash position.
  • Product-sales growth, funding execution and progress toward regulatory milestones remain the key areas to watch.

Micro-X (ASX:MX1) is entering a new phase under chief executive Dr Brian Gonzales, with the company placing greater emphasis on turning its imaging technology into repeatable commercial sales.

The Leadership change comes alongside new funding, continued Investment in medical CT and a Balance Sheet that still requires close attention. For investors, the core question is increasingly straightforward: can Micro-X translate a decade of technology development into a larger and more durable product-revenue base?

Leadership reset

In early August 2026, Micro-X (ASX:MX1) appointed Dr Brian Gonzales as chief executive, succeeding Kingsley Hall.

Gonzales was already familiar with the business, having served as chief scientist and chief executive of the company’s Americas operations.

Hall remains available in an advisory capacity until early November 2026.

The leadership announcement was accompanied by commitments for A$8.0 million in convertible notes.

Later in August, Gonzales outlined a strategic reset that placed greater emphasis on medical CT and commercial execution.

The appointment therefore comes at a point when Micro-X is moving from technology development toward a sharper focus on revenue generation and market adoption.

What Micro-X actually sells

Micro-X (ASX:MX1) develops cold-cathode X-ray tubes using carbon nanotube technology, which underpins its Nano Electronic X-ray platform.

The core advantage is size and weight.

Because the technology does not rely on a heated filament, it can support smaller and lighter X-ray systems than traditional architectures.

However, the company’s commercial position remains narrower than its broader technology pipeline might suggest.

For FY2026, Micro-X reported revenue of A$15.09 million, up 16% from approximately A$13.1 million in the prior year.

Of that total, around A$5.4 million came from product sales, largely associated with the Rover Plus mobile digital radiography system.

The remaining A$9.7 million came from contracted project income linked to development programs.

Micro-X also reported A$9.0 million in other income, including approximately A$5.7 million from the Research and Development tax incentive and A$3.2 million from grants.

That distinction matters because project income, grants and tax incentives are different from recurring product sales.

For the commercial reset to gain traction, Rover Plus and future imaging products will need to make a larger contribution to the revenue mix.

The numbers behind the reset

Micro-X narrowed its FY2026 net loss to approximately A$9.88 million from A$13.90 million in the previous year.

Operating cash outflow was approximately A$8.9 million.

Cash stood at A$3.1 million at 30 June 2026, broadly unchanged from A$3.2 million a year earlier.

Against the level of operating cash use, that leaves the company with limited financial flexibility.

The FY2026 accounts also included a material uncertainty that may cast significant doubt on the group’s ability to continue as a going concern.

Micro-X has therefore continued to rely on external funding.

The company raised A$6.18 million through a Placement in late 2025 and subsequently secured commitments for A$8.0 million in convertible notes.

Those notes carry interest of 12% per annum, compounding monthly over three years, and convert at A$0.08 per share.

Automatic conversion is also linked to a higher share-price threshold measured over a 20-day volume-weighted average period.

Director participation in the notes remains subject to Shareholder approval.

Medical CT becomes more important

Medical CT sits at the centre of the company’s strategic reset.

Micro-X’s Head CT stroke scanner has entered a first human imaging pilot at Royal Melbourne Hospital.

The program is backed by A$8.0 million from the Medical Research Future Fund and A$4.4 million under the Industry Growth Program.

Clinical validation is targeted for completion by the end of FY2027, with regulatory submission expected after that stage.

The distinction remains important: clinical development and regulatory submission do not represent regulatory clearance or commercial sales.

The Head CT program still needs to progress through validation and regulatory review before it can become a meaningful commercial product.

US programs add scale, but with conditions

Micro-X (ASX:MX1) also has substantial development contracts in the United States.

Its ARPA-H full-body CT program is worth up to A$25 million, with A$12.5 million initially committed.

A separate Department of Homeland Security checkpoint program is worth up to A$31.7 million.

Around A$8.5 million had been drawn under that program, while a further A$1.3 million extension was secured in May 2026 following delays linked to US administrative processes.

These contracts provide meaningful funding for product development, but they remain different from commercial product sales.

They validate customer interest and help finance technical progress, but the longer-term commercial test is whether funded prototypes and development programs ultimately translate into repeat orders.

Funding remains central

The company’s funding position remains one of the most important parts of the story.

Micro-X expects to receive approximately A$2.4 million from the R&D tax incentive in October 2026 after repayment of A$3.0 million in principal and A$0.1 million in interest to Radium Capital.

The convertible-note funding also provides additional runway.

However, the combination of ongoing development expenditure, operating cash outflows and a relatively modest cash balance means Capital management remains critical.

The company needs to balance investment in Head CT and US programs with the requirement to grow commercial sales and improve cash generation.

What to watch

The first area to monitor is Rover Plus.

A sustained increase in product sales would provide clearer evidence that the company’s commercial focus is gaining traction.

The second is the shareholder vote associated with the convertible notes and completion of the broader funding package.

The third is the expected R&D tax receipt and how that affects near-term liquidity.

The fourth is progress in the Head CT program, particularly completion of clinical validation and movement toward regulatory submission.

For Micro-X (ASX:MX1), the leadership transition marks a change in emphasis rather than a completed turnaround. The company has established differentiated technology and secured several funded development programs, but the next phase will depend on whether that technical capability can be converted into repeat product sales and a more sustainable financial model.